Physician profile
Mark Patterson
NPI 1285377929
$1,847.72
in general payments reported to CMS, 2019-2025
14 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.02 · 2023: $251 · 2024: $1,049 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $972 · Food and Beverage: $727 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $971.94 |
| Food and Beverage | $726.76 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $971.94 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $409.23 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $117.01 | 2024-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $89.57 | 2022-2023 | |
| Lilly USA, LLC | $68.67 | 2023 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $28.63 | 2023 | Polivy, Lunsumio, Columvi |
| Acadia Pharmaceuticals INC | $27.60 | 2024 | Nuplazid |
| Amgen INC. | $23.85 | 2023 | Lumakras |
| Eisai INC. | $22.21 | 2023 | |
| Novartis Pharmaceuticals Corporation | $20.64 | 2022 | |
| Lundbeck LLC | $20.60 | 2024 | Rexulti |
| Incyte Corporation | $16.73 | 2023 | Pemazyre, Monjuvi |
| Seagen INC. | $15.99 | 2023 | Tukysa |
| Genzyme Corporation | $15.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.